InVivo surges 56% on news of impending U.S. trial, search for strategic partnerships

November 16, 2013 by Arezu Sarvestani

Shares of InVivo Therapeutics gain more than 50% by the end of the day Friday after the company announces that it's ready to set aside its hydrogel product development to focus on an upcoming clinical trial of its degradable spinal scaffold.

InVivo surges 56% on clinical trial news for spinal scaffold

Get the complete picture with a MassDevice Plus membership. Registered users can login here.